Zymeworks is a privately held biotherapeutics company that is developing best-in-class Azymetric™ bi-specific antibodies and antibody drug conjugates for the treatment of cancer, autoimmune and inflammatory diseases. The company’s novel Azymetric™, AlbuCORE™, and EFECT™ platforms, and its proprietary ZymeCAD™ structure-guided protein engineering technology, enable the development of highly potent bi-specific antibodies and multivalent protein therapeutics across a range of indications. Zymeworks is focused on accelerating its preclinical biotherapeutics pipeline through in-house research and development programs and strategic collaborations.
Zymeworks is a BDC Capital Healthcare Venture Fund company, co-managed in partnership by Amplitude Venture Capital.
Dion Madsen, Founding partner at Amplitude Venture Capital.
Zymeworks $85 Million IPO Puts Spotlight on Canada’s Biotech SectorLearn More
Zymeworks Completes Acquisition of Kairos Therapeutics Creating a Leader in Biologics Drug Discovery and DevelopmentLearn More
Zymeworks Receives LifeSciences BC Life Sciences Company of the Year AwardLearn More
Zymeworks Announces $61.5 Million Financing to Support the Clinical Development of its Pipeline of Azymetric™ Antibody TherapeuticsLearn More
Certain news link to external sites and are presented in French only.